Gallop Oncology

Gallop Oncology is a clinical-stage, wholly-owned subsidiary of PureTech Health developing first-in-class therapies targeting galectin-9. Its lead asset, LYT-200, has received FDA Fast Track and Orphan Drug designations for acute myeloid leukemia (AML) and head and neck squamous cell carcinoma (HNSCC), demonstrating a dual mechanism of action that combines direct tumor suppression with immune modulation. The company is advancing LYT-200 in Phase 1/2 trials for these high-need indications, with initial clinical data showing promising safety and activity. Gallop represents a focused effort to address significant unmet needs in oncology through a novel biological pathway.

Development of fully human monoclonal antibodies targeting galectin-9, a protein that drives tumor progression and immune evasion. The platform aims for a dual mechanism of action: direct induction of tumor cell apoptosis and restoration of anti-tumor immune response by blocking immunosuppressive signaling.

In AML, competitors include other novel targeted agents (e.g., IDH, FLT3 inhibitors) and next-generation venetoclax combinations. In HNSCC, the landscape is dominated by PD-1 inhibitors and numerous combination trials. Gallop's key differentiation is its first-in-class focus on galectin-9, aiming to simultaneously attack the tumor and reverse a broad immunosuppressive network, a mechanism distinct from single-checkpoint inhibitors.